JCM
ANIP icon

Julex Capital Management’s ANI Pharmaceuticals ANIP Stock Holding History

Julex Capital Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10
Closed -$705 – 148
2019
Q1 		$705 Hold
10
– – ﹤0.01% 138
2018
Q4 		$0 Buy
+10
New +$524 ﹤0.01% 112

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return

Julex Capital Management's ANIP Position: Q2 2019 in Review

Julex Capital Management sold out of ANI Pharmaceuticals (ANIP) in Q2 2019, closing a stake of 10 shares — an estimated $705 sold.

Julex Capital Management first reported a position in ANIP in Q4 2018 and held it in 2 quarters. The position peaked at $705 in Q1 2019. 196 funds tracked by Wall St. Rank hold ANIP as of Q2 2019.

  • Julex Capital Management reported no remaining ANI Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Julex Capital Management sold 10 ANI Pharmaceuticals shares in Q2 2019, an estimated $705.
  • Julex Capital Management first reported a position in ANI Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Julex Capital Management's ANI Pharmaceuticals position peaked at $705 in Q1 2019.
  • 196 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2019.

Based on Julex Capital Management's 13F filing for Q2 2019, filed 29 Oct 2019.